Back to search

Peptide record

TPDB06824

Antibacterial Anticancer Antifungal Toxicity standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06824
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb dbAMP
standard
No
A 12-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
AKRHHGYKRKFH
Physicochemical Analysis
C71H109N27O14
NDCEQILMPSTWV
HK
1564.82
11.59
8
0
3
+5
5.24
-2.283
8.33
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
95.22
1
Residue Composition
number
1
A
2
R
0
N
0
D
0
C
0
E
0
Q
1
G
3
H
0
I
0
L
3
K
0
M
1
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 1 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 3 I: 0 L: 0 K: 3 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
12
C71H109N27O14
1564.82
11.59
+5
5.24
-2.283
Evidence Records 16 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.78-12.5 µg/mL

Target

C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
ctive against C. albicans (LD50 2.3 ug/ml LD90 4.7 ug/ml). Also active against 5 strains C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5
Evidence 2 Activity

Activity

MIC
Antibacterial
6.25-12.5 µg/mL

Target

C. krusei ATCC 6258 or HIV patient

Source & Reference

dbAMP

Other

0028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV
Evidence 3 Activity

Activity

MIC
Antibacterial
0.78 µg/mL

Target

C. parapsilosis ATCC 22019

Source & Reference

dbAMP

Other

rata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensi
Evidence 4 Activity

Activity

MIC
Antibacterial
0.78-1.56 µg/mL

Target

C. tropicalis ATCC 13803 and HIV patient

Source & Reference

dbAMP

Other

C 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Bo
Evidence 5 Activity

Activity

MIC
Antibacterial
6.25 µg/mL

Target

C. dubliniensis HIV patient

Source & Reference

dbAMP

Other

IC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active
Evidence 6 Activity

Activity

MIC
Antibacterial
25 µg/mL

Target

C. glabrata HIV patient

Source & Reference

dbAMP

Other

strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active against C. albicans, but only the D-for
Evidence 7 Activity

Activity

MIC
Antifungal
0.78-12.5 µg/mL

Target

C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
ctive against C. albicans (LD50 2.3 ug/ml LD90 4.7 ug/ml). Also active against 5 strains C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5
Evidence 8 Activity

Activity

MIC
Antifungal
6.25-12.5 µg/mL

Target

C. krusei ATCC 6258 or HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

0028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV
Evidence 9 Activity

Activity

MIC
Antifungal
0.78 µg/mL

Target

C. parapsilosis ATCC 22019

Source & Reference

dbAMP CAFPdb Antifungipept

Other

rata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensi
Evidence 10 Activity

Activity

MIC
Antifungal
0.78-1.56 µg/mL

Target

C. tropicalis ATCC 13803 and HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

C 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Bo
Evidence 11 Activity

Activity

MIC
Antifungal
6.25 µg/mL

Target

C. dubliniensis HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

IC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active
Evidence 12 Activity

Activity

MIC
Antifungal
25 µg/mL

Target

C. glabrata HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active against C. albicans, but only the D-for
Evidence 13 Activity

Activity

1% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
1% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole. | J Antimicrob Chemother | 2004
Evidence 14 Activity

Activity

50% Hemolysis
Toxicity
>192 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >192 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The Antimicrobial Peptides P-113Du and P-113Tri Function against Candida albicans. | Antimicrob Agents Chemother | 2016
Evidence 15 Activity

Activity

0% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 50 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Dependence on size and shape of non-nature amino acids in the enhancement of lipopolysaccharide (LPS) neutralizing activities of antimicrobial peptides. | J Colloid Interface Sci | 2019
Evidence 16 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human fibroblasts

Target

Human fibroblasts

Source & Reference

NA
DBAASP
Dependence on size and shape of non-nature amino acids in the enhancement of lipopolysaccharide (LPS) neutralizing activities of antimicrobial peptides. | J Colloid Interface Sci | 2019